

Makrolidresistentes *Mycoplasma pneumoniae*: reale Gefahr jetzt auch in der Schweiz

***Mycoplasma pneumoniae* résistant aux macrolides: la menace est une réalité suisse aujourd'hui**

Literatur / Références

- 1 Marrie TJ. Mycoplasma pneumoniae pneumonia requiring hospitalization, with emphasis on infection in the elderly. Arch Intern Med. 1993;153:438–94.
- 2 Tschan A, Weisser M, Frank B, Dumke R, Tamm M, Imhof E, Laifer G. Schwere Pneumonien mit Makrolid-Resistenten Mycoplasmen in der Schweiz. Forum Médical Suisse. 2012;12:961–3.
- 3 Welti M, Jatou K, Altwegg M, Sahli R, Wenger A, Bille J. Development of a multiplex real-time quantitative PCR assay to detect Chlamydia pneumoniae, Legionella pneumophila and Mycoplasma pneumoniae in respiratory tract secretions. Diagn Microbiol Infect Dis. 2003;45(2):85–95.
- 4 Lamoth F, Greub G. Fastidious intracellular bacteria as causal agents of community-acquired pneumonia. Expert Rev Anti Infect Ther. 2010;8:775–90.
- 5 Matsuoka M, Narita M, Okazaki N, Ohya H, Yamazaki T, Ouchi K, et al. Characterization and molecular analysis of macrolide-resistant Mycoplasma pneumoniae clinical isolates obtained in Japan. Antimicrob Agents Chemother. 2004;48(12):4624–30.
- 6 File TM Jr, Segreti J, Dunbar L, Player R, Kohler R, Williams RR, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother. 1997;41(9):1965–72.
- 7 Patel T, Pearl J, Williams J, Haverstock D, Church D. Efficacy and safety of ten day moxifloxacin 400 mg once daily in the treatment of patients with community-acquired pneumonia. Community Acquired Pneumonia Study Group. Respir Med. 2000;94(2):97–105.
- 8 Gruson D, Pereyre S, Renaudin H, Charron A, Bébéar C, Bébéar CM. In vitro development of resistance to six and four fluoroquinolones in Mycoplasma pneumoniae and Mycoplasma hominis, respectively. Antimicrob Agents Chemother. 2005;49(3):1190–3.
- 9 Suzuki S, Yamazaki T, Narita M, Okazaki N, Suzuki I, Andoh T, et al. Clinical evaluation of macrolide-resistant Mycoplasma pneumoniae. Antimicrob Agents Chemother. 2006;50(2):709–12.